A Multi-Center, Open-Label, Two-Part Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics of RO7079901
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Nacubactam (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Roche
- 09 Aug 2017 Status changed from recruiting to completed.
- 19 Apr 2017 Planned End Date changed from 30 Jun 2017 to 25 Jul 2017.
- 19 Apr 2017 Planned primary completion date changed from 30 Jun 2017 to 25 Jul 2017.